Inferra AI / Company / RYTM
Rhythm Pharmaceuticals, Inc.
RYTM · Health Care
Last earnings Aug 4, 2026
Key results
Revenuequarter
$48.5 million
htm EX-99.1 Exhibit 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update -- Second quarter 2025 net product revenue from global sales of IMCIVREE (setmelanotide) of $48.5 million -- -- U.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Second Quarter and Recent Business Highlights Revenue from global sales of IMCIVREE was $48.5 million for the second quarter of 2025, an increase of 29% percent on a sequential basis from the first quarter of 2025, primarily driven by sales of IMCIVREE for the treatment of patients with Bardet-Biedl syndrome (BBS).
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
In the second quarter of 2025, revenue of $32.0 million, or 66% of product revenue, was generated in the United States, an increase of 31% on a sequential basis.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Revenue of $16.5 million, or 34% of product revenue, was generated outside the United States, a sequential increase of 24%
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Revenue: Net product revenues relating to global sales of IMCIVREE were $48.5 million for the second quarter of 2025, as compared to $29.1 million for the second quarter of 2024.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Year to Date 2025 Financial Results: Revenue: Net product revenues relating to sales of IMCIVREE were $86.2 million for the six months ended June 30, 2025, as compared to $55.0 million for the six months ended June 30, 2024.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q2 2025 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance · company-stated
No guidance located in the held release
Capital allocation
In the future, the Company will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, proceeds from out license arrangements, product sales and funded research and development programs to maintain the Company's operations and meet the Company's obligations.
To the extent the amortized cost basis of the available-for-sale debt securities exceeds the fair value, management assesses the debt securities for credit loss; however, management considers the risk of credit loss to be minimized by the Company's policy of investing in financial instruments issued by highly-rated financial institutions.
Event summary
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
In the future, the Company will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, proceeds from out license arrangements, product sales and funded research and development programs to maintain the Company's operations and meet the Company's obligations.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
To the extent the amortized cost basis of the available-for-sale debt securities exceeds the fair value, management assesses the debt securities for credit loss; however, management considers the risk of credit loss to be minimized by the Company's policy of investing in financial instruments issued by highly-rated financial institutions.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
During the three and six months ended June 30, 2026 and 2025, the Company did not recognize any credit losses related to its available-for-sale debt securities.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Further, as of June 30, 2026 and December 31, 2025, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Deferred Royalty Obligation The Company treats the debt obligation to HealthCare Royalty Management, LLC as discussed further in Note 13, Long-Term Obligations , as a deferred royalty obligation, amortized using the effective interest rate method over the estimated life of the revenue streams.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
The financial assets valued based on Level 2 inputs consist of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Strategy & priorities
(Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2025.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
In addition, Rhythm announced today that it plans to host Commercial Readiness for Acquired Hypothalamic Obesity , an in-person and webcasted event for investors and analysts, on September 24, 2025, in Boston to review its global launch strategy for setmelanotide.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Management uses this non-GAAP financial measure for planning purposes, including the preparation of our internal annual operating budget and financial projections; to evaluate the performance and effectiveness of our operational strategies; and to evaluate our capacity to expand our business.
SEC original ↗Rhythm Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
We are focused on advancing our melanocortin-4 receptor agonists, including our lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by MC4R pathway diseases.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
To the extent the amortized cost basis of the available-for-sale debt securities exceeds the fair value, management assesses the debt securities for credit loss; however, management considers the risk of credit loss to be minimized by the Company's policy of investing in financial instruments issued by highly-rated financial institutions.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Risks & headwinds
Legal Proceedings 42 Item 1A.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
The Company is subject to risks and uncertainties common to commercial-stage companies in the biotechnology industry, including but not limited to, risks associated with the commercialization of approved products, completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
The inability of the vendors to fulfill testing services for the Company could materially impact future operating results and adversely impact our ability to further develop setmelanotide.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Inventory Prior to receiving approval from the FDA in November 2020 to sell IMCIVREE in the United States, the Company expensed all costs incurred related to the manufacture of IMCIVREE as research and development expense because of the inherent risks associated with the development of a drug candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.
SEC original ↗Rhythm Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Earnings deck slides
0 decks with slide viewRhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Rhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Rhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Rhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Rhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Rhythm Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
35 documents- Q2 2026
- 10-QRYTM
- 8-KRYTM
- Q1 2026
- 8-KRYTM
- 8-KRYTM
- 10-QRYTM
- 8-KRYTM
- 8-KRYTM
- Q4 2025
- 8-KRYTM
- 8-KRYTM
- EX-99RYTM
- 8-KRYTM
- EX-99RYTM
- 8-KRYTM
- EX-99RYTM
- 10-KRYTM
- 8-KRYTM
- 8-KRYTM
- Q3 2025
- 8-KRYTM
- 8-KRYTM
- EX-99RYTM
- 8-KRYTM
- EX-99RYTM
- 10-QRYTM
- 8-KRYTM
- Q2 2025
- 10-QRYTM
- 8-KRYTM
- 8-KRYTM
- 8-KRYTM
- Q1 2025
- 8-KRYTM
- 10-QRYTM
- 8-KRYTM
- 8-KRYTM
- Q4 2024
- 8-KRYTM
- 8-KRYTM
- 10-KRYTM
Earnings releases
13 documentsPresentations
6 documents
Transcripts
0 documentsNo transcripts for Rhythm Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.